Stabilization of mutant BRCA1 protein confers PARP inhibitor and platinum resistance

Breast Cancer Type 1 Susceptibility Protein (BRCA1)-deficient cells have compromised DNA repair and are sensitive to poly(ADP-ribose) polymerase (PARP) inhibitors. Despite initial responses, the development of resistance limits clinical efficacy. Mutations in the BRCA C-terminal (BRCT) domain of BRC...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Johnson, Neil, Johnson, Shawn F., Yao, Wei, Li, Yu-Chen, Choi, Young-Eun, Bernhardy, Andrea J., Wang, Yifan, Capelletti, Marzia, Sarosiek, Kristopher A., Moreau, Lisa A., Chowdhury, Dipanjan, Wickramanayake, Anneka, Harrell, Maria I., Liu, Joyce F., D’Andrea, Alan D., Miron, Alexander, Swisher, Elizabeth M., Shapiro, Geoffrey I.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: National Academy of Sciences 2013
Gaiak:
Biological Sciences
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC3801063/
https://ncbi.nlm.nih.gov/pubmed/24085845
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1073/pnas.1305170110
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak